No Data
No Data
Calculating The Fair Value Of Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Shandong Pharmaceutical GlassLtd fair value estimate is CN¥24.29 With CN¥28.73 share price, Shandong Pharmaceutical GlassLtd appears to be tr
Shandong Pharmaceutical (600529): Borosilicate growth increases gross profit costs, increases profits
Event: Total operating income of 4.982 billion yuan (+18.98%); net profit to mother of 776 million yuan (+25.48%); net profit after deducting non-return to mother of 742 million yuan (+23.07%) was achieved in 2023. 2
Shandong Pharmaceutical Glass (600529): Good performance growth, borosilicate products continue to gain strength
Incident: The company disclosed its 2024 quarterly report, achieving operating income of 1,267 million yuan, an increase of 2.50% year on year; net profit to mother of 221 million yuan, up 32.59% year on year; deducted non-net profit of 210 million yuan, same
Shandong Pharmaceutical Glass (600529): Continuous optimization of product structure and further enhancement of market competitiveness
The company achieved operating income of 4.982 billion yuan in 2023, an increase of 18.98% over the previous year; net profit after deduction was 742 million yuan, an increase of 23.07% over the previous year. Achieving a basic EPS is 1.17 yuan. 20
Shandong Pharmaceutical (600529): Borosilicate emissions have accelerated and profits have improved significantly
The incident described achieving revenue of 4.982 billion yuan in 2023, up 18.98% year on year; attributable net profit of 776 million, up 25.48% year on year; deducted non-net profit of 742 million yuan, up 23.07% year on year
Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a sad week for Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529), who've watched their investment drop 11% to CN¥28.48 in the week since the company reported its quarterly result. The
No Data